Profiling Cisplatin Resistance in Head and Neck Cancer: A Critical Role of the VRAC Ion Channel for Chemoresistance

• Published in: Cancers 2021-09, Vol.13 (19), p.4831
• Main Authors: Siemer, Svenja, Fauth, Torsten, Scholz, Paul, Al-Zamel, Yara, Khamis, Aya, Gül, Désirée, Freudelsperger, Laura, Wollenberg, Barbara, Becker, Sven, Stauber, Roland H, Hagemann, Jan
• Format: Article
• Language: English
• Subjects: Apoptosis; Biomarkers; Cancer therapies; Cell culture; Chemoresistance; Chemotherapy; Cisplatin; CRISPR; Disease; DNA damage; Doxorubicin; Drug resistance; Gene expression; Head & neck cancer; Hypotheses; Medical prognosis; Next-generation sequencing; Paclitaxel; Patients; Proteins; Therapeutic targets; Transcription factors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13194831

Treatment success of head and neck cancers (HNSCC) is often hindered by tumor relapses due to therapy resistances. This study aimed at profiling cisplatin resistance mechanisms and identifying biomarkers potentially suitable as drug targets and for patient stratification. Bioinformatic analyses of suggested resistance factors in a cohort of 565 HNSCC patients identified the VRAC ion channel as a clinically relevant indicator for recurrent diseases following radiochemotherapy ( = 0.042). Other drug import/export transporters, such as CTR1, OCT1, or MRP1, were found to be less relevant. To experimentally verify VRAC's critical role for cisplatin resistance, we used CRISPR/Cas9 knockout resulting in cisplatin-resistant HNSCC cells, which could be resensitized by VRAC expression. Next-generation sequencing further underlined VRAC's importance and identified VRAC-regulated signaling networks, potentially also contributing to cisplatin resistance. CTR1, OCT1, or MRP1 did not contribute to increased cisplatin resistance. In addition to two-dimensional HNSCC models, three-dimensional tumor spheroid cultures confirmed VRAC's unique role for cisplatin sensitivity. Here, resistance correlated with DNA damage and downstream apoptosis. The cisplatin specificity of the identified VRAC pathway was verified by testing paclitaxel and doxorubicin. Our results were independently confirmed in naturally occurring, cisplatin-resistant HNSCC cancer cell models. Collectively, we here demonstrate VRAC's role for cisplatin resistance in HNSCC and its relevance as a potential drug target and/or prognostic biomarker for chemotherapy resistance.